C12N 2770/24371
Demonstrated in vivo effect
C12N2770/24371 (Demonstrated in vivo effect) appears on 6 US grants and 10 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 10
- Assignees
- 13
- Inventors
- 30
- Latest grant
- 1 Nov 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 2 |
| 2015 | 0 | 1 |
| 2016 | 2 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Vaccine composition for classical swine fever and preparation method thereof1 Nov 2022US 11,484,589 B2Bioapplications Inc.
- Liposomal adjuvant compositions29 Oct 2019US 10,456,459 B2Zoetis Services LLC
- Recombinant low virulence bovine herpesvirus-1 (BoHV-1) vaccine vectors19 Jun 2018US 9,999,661 B2Meat & Livestock Australia Limited
- Recombinant low virulence bovine herpesvirus-1 (BoHV-1) vaccine vectors5 Jul 2016US 9,381,240 B2Meat & Livestock Australia Limited
- Live attenuated antigenically marked classical swine fever vaccine31 May 2016US 9,352,032 B2The United States of America as represented by the Secretary of Agriculture
- Recombinant classical swine fever virus e2 protein with b/c domain swapping17 Jul 2025US 2025/0230194 A1Boehringer Ingelheim Vetmedica (China) Co., Ltd.
- Recombinant classical swine fever virus15 Jun 2023US 2023/0181710 A1
- Vaccine composition for classical swine fever and preparation method thereof17 Sep 2020US 2020/0289641 A1Bioapplications Inc.
- Pestivirus marker vaccine8 Aug 2019US 2019/0240311 A1Intervet Inc.
- Liposomal adjuvant compositions25 Jan 2018US 2018/0021424 A1Zoetis Services LLC
Most cited
By later US patents